氯雷他定联合孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效观察

Clinical effect of loratadine combined with montelukast on children with cough variant asthma

目的观察氯雷他定联合孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床疗效。方法 2015年1月至2016年1月周口市中心医院小儿内科收治住院的咳嗽变异性哮喘患儿80例,随机分为观察组和对照组各40例。对照组给予孟鲁司特钠咀嚼片口服,每次5mg,每日1次,治疗3个月。观察组在对照组治疗基础上口服氯雷他定片,每日睡前服用,每次5 mg,连续服用2周。停药观察2个月,比较两组患儿的临床症状、体征缓解情况及治疗效果。结果观察组治疗总有效率为95.0%(38/40),显著高于对照组77.5%(31/40),差异有统计学意义(P<0.05)。观察组咳嗽消失时间、哮喘持续时间及咳痰消失时间均短于对照组,差异有统计学意义(P<0.05)。结论氯雷他定联合孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效明显。

Objective To study the clinical effect of loratadine combined with montelukast on children with cough variant asthma. Methods From Jan. 2015 to Jan. 2016, a total of 80 children with cough variant asthma hospitalized in our hospital for treatment were taken as the clinical research objects, and they were randomly divided into control group（40 cases）and treatment group（40 cases）. Both groups were treated with montelukast chewable tablets,5 mg per time, once a day for 3 months; besides, the treatment group was additionally given loratadine 5 mg before bedtime for continuous 2 months. The clinical efficacy and im- provement of physical signs and symptoms in the two groups were compared after stopping the treatment for 2 months. Results The total effective rate in the treatment group was 95.0 %, which was significantly high- er than that in the control group（77.5 %,P〈0. 05） ;the disappearance time of cough and expectoration, and asthma duration in the treatment group were all shorter than those in the control group（P〈0.05）. Conclusion Loratadine combined with montelukast has significant effect in the treatment of children with cough variant asthma.